Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | -925.00K | 925.00K | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -3.18M | -2.32M | -3.26M | -3.20M | -2.28M | -1.82M |
EBITDA | -81.20M | -71.89M | -52.29M | -51.99M | -49.59M | -31.46M |
Net Income | -84.39M | -75.14M | -36.32M | -55.19M | -50.52M | -33.28M |
Balance Sheet | ||||||
Total Assets | 297.32M | 335.73M | 222.57M | 109.27M | 101.49M | 210.52M |
Cash, Cash Equivalents and Short-Term Investments | 274.52M | 312.40M | 197.16M | 82.02M | 70.54M | 192.56M |
Total Debt | 10.97M | 12.43M | 16.25M | 4.69M | 5.21M | 12.12M |
Total Liabilities | 24.06M | 25.36M | 36.55M | 255.00M | 193.36M | 19.30M |
Stockholders Equity | 273.25M | 310.38M | 186.02M | -145.74M | -91.88M | 191.22M |
Cash Flow | ||||||
Free Cash Flow | -74.51M | -71.41M | -51.74M | -55.05M | -64.77M | -26.79M |
Operating Cash Flow | -73.30M | -70.60M | -51.42M | -52.82M | -46.40M | -24.57M |
Investing Cash Flow | -169.18M | -125.26M | 25.64M | -2.23M | -18.37M | -2.22M |
Financing Cash Flow | 190.25M | 184.07M | 92.48M | 66.53M | 51.06M | 77.14M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $246.01M | ― | -32.38% | ― | ― | 23.24% | |
46 Neutral | $242.78M | ― | -99.23% | ― | ― | ― | |
36 Underperform | $288.47M | ― | -85.21% | ― | ― | 38.94% | |
34 Underperform | $368.64M | ― | -39.41% | ― | -100.00% | -24.84% | |
33 Underperform | $228.49M | ― | -125.43% | ― | ― | -686.12% | |
30 Underperform | $171.88M | ― | -9999.00% | ― | ― | -4.60% |
Neurogene has updated its corporate presentation, highlighting the progress and future plans for its NGN-401 program for Rett syndrome, which is currently in Phase 1/2 clinical trials. The company is leveraging its proprietary EXACT technology and in-house manufacturing to advance its pipeline and explore market opportunities, positioning itself strategically in the biopharmaceutical sector.